 Stephani Stancil
Concepts (113)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Naltrexone | 3 | 2022 | 4 | 2.310 |
Why?
| | Metronidazole | 3 | 2024 | 16 | 1.520 |
Why?
| | Narcotic Antagonists | 2 | 2021 | 3 | 1.470 |
Why?
| | Adolescent | 16 | 2024 | 2197 | 1.340 |
Why?
| | Contraceptive Agents | 2 | 2021 | 13 | 1.300 |
Why?
| | Contraception | 5 | 2024 | 30 | 1.150 |
Why?
| | Humans | 20 | 2024 | 6896 | 1.130 |
Why?
| | Microsomes, Liver | 2 | 2024 | 44 | 1.120 |
Why?
| | Female | 15 | 2024 | 3525 | 0.980 |
Why?
| | Opioid-Related Disorders | 2 | 2021 | 15 | 0.950 |
Why?
| | Adult | 9 | 2024 | 1181 | 0.940 |
Why?
| | Anticonvulsants | 1 | 2024 | 25 | 0.920 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2024 | 14 | 0.920 |
Why?
| | Food-Drug Interactions | 1 | 2022 | 1 | 0.850 |
Why?
| | Liver | 1 | 2023 | 126 | 0.840 |
Why?
| | Young Adult | 8 | 2024 | 647 | 0.830 |
Why?
| | Adolescent Psychiatry | 1 | 2022 | 3 | 0.810 |
Why?
| | Anxiety Disorders | 1 | 2022 | 19 | 0.800 |
Why?
| | Child | 8 | 2024 | 3364 | 0.790 |
Why?
| | Nitroimidazoles | 1 | 2021 | 1 | 0.780 |
Why?
| | Male | 11 | 2024 | 3337 | 0.780 |
Why?
| | Tuberculosis, Multidrug-Resistant | 1 | 2021 | 2 | 0.780 |
Why?
| | Antitubercular Agents | 1 | 2021 | 7 | 0.780 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 17 | 0.740 |
Why?
| | Bulimia Nervosa | 1 | 2019 | 1 | 0.680 |
Why?
| | Binge-Eating Disorder | 1 | 2019 | 1 | 0.680 |
Why?
| | Nicotine | 1 | 2019 | 10 | 0.660 |
Why?
| | Cytochrome P-450 CYP2A6 | 1 | 2019 | 4 | 0.660 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 40 | 0.630 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 20 | 0.620 |
Why?
| | Counseling | 2 | 2024 | 28 | 0.590 |
Why?
| | Abnormalities, Drug-Induced | 1 | 2015 | 8 | 0.530 |
Why?
| | Feasibility Studies | 4 | 2024 | 58 | 0.520 |
Why?
| | Adolescent Health Services | 3 | 2021 | 10 | 0.520 |
Why?
| | Middle Aged | 4 | 2024 | 608 | 0.510 |
Why?
| | Models, Biological | 2 | 2024 | 65 | 0.450 |
Why?
| | Pregnancy | 5 | 2024 | 216 | 0.440 |
Why?
| | Cytosol | 2 | 2023 | 14 | 0.430 |
Why?
| | Metabolic Clearance Rate | 2 | 2023 | 18 | 0.430 |
Why?
| | Emergency Service, Hospital | 3 | 2024 | 130 | 0.420 |
Why?
| | Cross-Over Studies | 2 | 2022 | 35 | 0.380 |
Why?
| | Retrospective Studies | 3 | 2020 | 1296 | 0.340 |
Why?
| | Drug Prescriptions | 2 | 2020 | 20 | 0.320 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 187 | 0.310 |
Why?
| | Electronic Health Records | 2 | 2021 | 64 | 0.310 |
Why?
| | United States | 3 | 2021 | 669 | 0.300 |
Why?
| | Pregnancy in Adolescence | 2 | 2024 | 9 | 0.280 |
Why?
| | Pregnancy, Unplanned | 2 | 2023 | 9 | 0.250 |
Why?
| | Genotype | 2 | 2024 | 410 | 0.240 |
Why?
| | Infant, Newborn | 3 | 2024 | 816 | 0.240 |
Why?
| | HLA-B Antigens | 1 | 2024 | 7 | 0.230 |
Why?
| | Sexual Behavior | 2 | 2021 | 38 | 0.230 |
Why?
| | Proteins | 1 | 2023 | 27 | 0.220 |
Why?
| | Adolescent Behavior | 2 | 2021 | 43 | 0.220 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2024 | 96 | 0.220 |
Why?
| | Health Education | 1 | 2023 | 26 | 0.220 |
Why?
| | Area Under Curve | 1 | 2022 | 35 | 0.210 |
Why?
| | Pharmacogenetics | 1 | 2024 | 176 | 0.200 |
Why?
| | Biotransformation | 1 | 2021 | 49 | 0.200 |
Why?
| | Harm Reduction | 1 | 2021 | 3 | 0.200 |
Why?
| | Extensively Drug-Resistant Tuberculosis | 1 | 2021 | 1 | 0.200 |
Why?
| | Anxiety | 1 | 2022 | 51 | 0.190 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 35 | 0.190 |
Why?
| | Employment | 1 | 2021 | 5 | 0.190 |
Why?
| | Biomarkers | 1 | 2022 | 136 | 0.190 |
Why?
| | Attitude | 1 | 2021 | 10 | 0.190 |
Why?
| | Insurance, Health | 1 | 2021 | 16 | 0.190 |
Why?
| | Motivational Interviewing | 1 | 2021 | 19 | 0.190 |
Why?
| | Patient Acceptance of Health Care | 1 | 2021 | 35 | 0.190 |
Why?
| | Obsessive-Compulsive Disorder | 1 | 2020 | 6 | 0.190 |
Why?
| | Prescription Drugs | 1 | 2020 | 4 | 0.190 |
Why?
| | Academic Medical Centers | 1 | 2020 | 11 | 0.190 |
Why?
| | Esophagitis | 1 | 2020 | 7 | 0.190 |
Why?
| | Gastritis | 1 | 2020 | 12 | 0.190 |
Why?
| | Aged | 1 | 2021 | 378 | 0.180 |
Why?
| | Infant | 2 | 2024 | 1446 | 0.180 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2020 | 18 | 0.180 |
Why?
| | Child, Preschool | 2 | 2024 | 1569 | 0.180 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2020 | 46 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 94 | 0.180 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2020 | 60 | 0.180 |
Why?
| | Depression | 1 | 2020 | 69 | 0.180 |
Why?
| | Off-Label Use | 1 | 2019 | 5 | 0.170 |
Why?
| | Vomiting | 1 | 2019 | 23 | 0.170 |
Why?
| | Healthy Volunteers | 1 | 2019 | 8 | 0.170 |
Why?
| | Reproductive Health Services | 1 | 2019 | 3 | 0.160 |
Why?
| | Hospitalists | 1 | 2019 | 7 | 0.160 |
Why?
| | Animals | 1 | 2021 | 729 | 0.160 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 42 | 0.160 |
Why?
| | Polymorphism, Genetic | 1 | 2019 | 90 | 0.160 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 115 | 0.160 |
Why?
| | Drug Stability | 1 | 2018 | 4 | 0.160 |
Why?
| | Limit of Detection | 1 | 2018 | 4 | 0.160 |
Why?
| | Decision Support Systems, Clinical | 1 | 2018 | 17 | 0.160 |
Why?
| | Pilot Projects | 3 | 2024 | 120 | 0.160 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2020 | 184 | 0.160 |
Why?
| | Linear Models | 1 | 2018 | 56 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 85 | 0.150 |
Why?
| | Reproducibility of Results | 1 | 2018 | 199 | 0.150 |
Why?
| | Teratogens | 1 | 2015 | 4 | 0.130 |
Why?
| | Proteomics | 1 | 2024 | 24 | 0.060 |
Why?
| | Age Factors | 1 | 2024 | 210 | 0.060 |
Why?
| | Program Evaluation | 1 | 2023 | 45 | 0.050 |
Why?
| | Contraception Behavior | 1 | 2020 | 13 | 0.040 |
Why?
| | Missouri | 1 | 2020 | 81 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2020 | 39 | 0.040 |
Why?
| | Pregnancy Complications | 1 | 2019 | 7 | 0.040 |
Why?
| | Risk | 1 | 2019 | 41 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2019 | 33 | 0.040 |
Why?
| | Clinical Competence | 1 | 2019 | 29 | 0.040 |
Why?
| | Quality Improvement | 1 | 2018 | 60 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 336 | 0.040 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 274 | 0.040 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|